Cargando…

Preclinical evaluation and first in human study of Al(18)F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer

PURPOSE: This study aimed to introduce a novel [(18)F]AlF-labeled ODAP-Urea-based Prostate-specific membrane antigen (PSMA) probe, named [(18)F]AlF-PSMA-137, which was derived from the successful modification of glutamate-like functional group. The preclinically physical and biological characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Ya’nan, Liu, Chen, Liu, Teli, Duan, Xiaojiang, Zhang, Qian, Liu, Jiayue, Wang, Pei, Guo, Qian, Yang, Xing, Du, Peng, Zhu, Hua, Yang, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633261/ https://www.ncbi.nlm.nih.gov/pubmed/36338719 http://dx.doi.org/10.3389/fonc.2022.1030187

Ejemplares similares

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
por: Ren, Ya’nan, et al.
Publicado: (2022)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods
por: UYGUR, EMRE, et al.
Publicado: (2023)

Synthesis, (123)I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures
por: Hasnowo, Lutfi A., et al.
Publicado: (2023)

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
por: Bertagna, Francesco, et al.
Publicado: (2020)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Design, Synthesis, Computational, and Preclinical Evaluation of (nat)Ti/(45)Ti-Labeled Urea-Based Glutamate PSMA Ligand
por: Søborg Pedersen, Kristina, et al.
Publicado: (2020)

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme
por: Novy, Zbynek, et al.
Publicado: (2019)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples
por: Schollhammer, Romain, et al.
Publicado: (2019)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
por: Sardana, Malvika, et al.
Publicado: (2022)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Automated sulfur-[(18)F]fluoride exchange radiolabelling of a prostate specific membrane antigen (PSMA) targeted ligand using the GE FASTlab™ cassette-based platform
por: Yang, Zixuan, et al.
Publicado: (2023)

Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
por: Cai, Huawei, et al.
Publicado: (2023)

Development of an Albumin-Based PSMA Probe With Prolonged Half-Life
por: Liu, Teli, et al.
Publicado: (2020)

Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake
por: Basuli, Falguni, et al.
Publicado: (2022)

State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET
por: Chomet, Marion, et al.
Publicado: (2021)

Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review)
por: Simon, Hélène, et al.
Publicado: (2023)

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
por: Abusalem, Mohammed, et al.
Publicado: (2023)

Optimized (68)Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Preclinical evaluation of carbon-11 and fluorine-18 sulfonamide derivatives for in vivo radiolabeling of erythrocytes
por: Gheysens, Olivier, et al.
Publicado: (2013)

Identification and characterization of the key enzyme in the biosynthesis of the neurotoxin β-ODAP in grass pea
por: Goldsmith, Moshe, et al.
Publicado: (2022)

Standardization of the [(68)Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
por: Fuscaldi, Leonardo L., et al.
Publicado: (2021)

Isotopic Radiolabeling of the Antiretroviral Drug [(18)F]Dolutegravir for Pharmacokinetic PET Imaging
por: Tisseraud, Marion, et al.
Publicado: (2022)

Synthesis, Fluorine-18 Radiolabeling, and In Vivo PET Imaging of a Hydrophilic Fluorosulfotetrazine
por: Beaufrez, Jason, et al.
Publicado: (2023)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
por: Murce, Erika, et al.
Publicado: (2023)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

Radiolabeling of Nanoparticles and Polymers for PET Imaging
por: Stockhofe, Katharina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_53muthempja1t79p18a770ugj1